MediWound Ltd. (MDWD)
| Market Cap | 103.53M |
| Revenue (ttm) | 23.17M |
| Net Income (ttm) | -9.59M |
| Shares Out | 27.25M |
| EPS (ttm) | -0.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $3.80 |
| Previous Close | $4.08 |
| Change ($) | -0.28 |
| Change (%) | -6.86% |
| Day's Open | 4.07 |
| Day's Range | 3.80 - 4.11 |
| Day's Volume | 149,348 |
| 52-Week Range | 2.90 - 6.22 |
MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC). In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma skin ca...
MediWound Ltd (NASDAQ: MDWD) has announced topline results from Phase 3 pediatric study with NexoBrid to treat severe thermal burns. The 145-subject study met its three primary endpoints.
NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD).
Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and D iabetic F oot U lcers
Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Bi...
Vericel Corporation's (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar removal ...
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application
Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy
Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021
MediWound (MDWD) delivered earnings and revenue surprises of 16.67% and 10.32%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
First Quarter Revenues of $5.8 Million, an Increase of 32% Year-over-Year
MediWound (NASDAQ:MDWD) releases its next round of earnings this Wednesday, May 05. Here is Benzinga's essential guide to MediWound's Q1 earnings report.
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
YAVNE, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and r...
Data Expected Second-Half 2021 Data Expected Second-Half 2021
Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time
YAVNE, Israel, Feb. 25, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and re...
MediWound (MDWD) delivered earnings and revenue surprises of 45.45% and 19.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Fourth Quarter Revenues of $6.7 Million - Up 23% and Full-Year 20 20 Revenues of $ 2 1.8 Million - Product Revenue Up 117%
Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
YAVNE, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...
YAVNE, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...
Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients
YAVNE, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...
MediWound recently reported an encouraging Q3 with a beat on EPS and revenue. It looks as if the company is easily weathering the pandemic with support from BARDA purchases. I have already established a...
Data to be Published in a Peer-Reviewed Journal in First Half 2021 Data to be Published in a Peer-Reviewed Journal in First Half 2021
YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...
MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2020 Results - Earnings Call Transcript
MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and 2.16%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of MediWound (NASDAQ:MDWD) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share rose 36.36% over the past year to ($0.07), which beat the estimate of ($...
Total Third Quarter R evenues of $6.6 Million Increased 29 % Y ear-over- Y ear
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...
Top-line Data is Expected in the Second Half of 2021 Top-line Data is Expected in the Second Half of 2021
Bromelain Degradation of Biofilms Could Provide Clinically Meaningful Benefits in Wound Healing Bromelain Degradation of Biofilms Could Provide Clinically Meaningful Benefits in Wound Healing
YAVNE, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in ...
MediWound: An Underfollowed Opportunity At A Discount
YAVNE, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in se...
YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedic...
Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2020 Results - Earnings Call Transcript
MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and -15.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Submitted Biological License Application to the FDA for NexoBrid EscharEx U.S. Phase 2 Study Resumed Patient Screening
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wou...
MediWound (MDWD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
YAVNE, Israel, June 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn...
Mediwound, An Attractive Opportunity Through The Coronavirus Crisis
About MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological dr... [Read more...]
| Industry Biotechnology | IPO Date Mar 20, 2014 |
| CEO Sharon Malka | Employees 75 |
| Stock Exchange NASDAQ | Ticker Symbol MDWD |
Analyst Forecasts
According to 5 analysts, the average rating for MediWound stock is "Strong Buy." The 12-month stock price forecast is 7.00, which is an increase of 84.21% from the latest price.